Thursday, June 11, 2026
Nationally Recognized Emergency Medicine Physician-Leader Michael E. Winters Named Chair of Emergency Medicine at UM School of Medicine
University of Maryland School of Medicine Dean Mark T. Gladwin, MD, along with University of Maryland Medical Center (UMMC) President Bert W. O’Malley, MD, today announced the appointment of Michael E. Winters, MD, MBA, as the permanent Chair of the Department of Emergency Medicine at the University of Maryland School of Medicine (UMSOM) and Chief of Emergency Medicine Clinical Services at UMMC. Dr. Winters, a nationally recognized leader in emergency medicine and critical care, has served as Interim Chair since September 2025 and will continue in the permanent role effective immediately.
Wednesday, June 10, 2026
UMSOM receives $1 million in State Grant Funding to Build New Center for Combat Casualty Care
Governor Wes Moore today announced that the University of Maryland School of Medicine will receive $1 million in grant funding through the Maryland Department of Commerce to establish a Center for Combat Casualty Care with the University of Maryland R Adams Cowley Shock Trauma Center (STC). The Center will include a 5,000-square-foot Sensitive Compartmented Information Facility (SCIF) for the research and development of new tools and treatments, and the training of military clinicians.
Tuesday, June 09, 2026
First-in-Human Clinical Trial Shows Promising Results for New Lassa Fever Vaccine
Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) reported encouraging results from an early clinical trial that tested a new dual vaccine against Lassa fever and rabies. The study, published today in the journal Nature Medicine, found that the vaccine was safe and induced immune responses against both viruses. There are currently no vaccines against Lassa fever on the market.
Wednesday, June 03, 2026
UM Greenebaum Comprehensive Cancer Center is First in Region to Offer Innovative Cell Therapy for Synovial Sarcoma
The University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) is the first in the Maryland, Delaware, Virginia, and Washington D.C. region to offer an innovative cell therapy treatment for patients with an advanced type of soft tissue cancer, known as synovial sarcoma. This single-infusion T-cell therapy, called TCR-T therapy, involves engineering a patient’s own white blood cells to recognize and attack cancer cells.
Tuesday, June 02, 2026
Bidding Farewell to the UMSOM Class of 2026
Four years ago this August, the new Dean of the University of Maryland School of Medicine walked through the school’s doors for the first time along with the Class of 2026. On May 14, 131 newly minted physicians from the Class of 2026 marked the culmination of their journey with Dean Mark T. Gladwin, MD at the historic Hippodrome Theatre, where they were celebrated by the families, mentors, and colleagues who helped carry them to this moment.
Monday, June 01, 2026
Five Minutes of Prayer Reduces Pain and Anxiety in Primary Care Patients, Randomized Trial Finds
A randomized controlled trial conducted at the University of Maryland School of Medicine has found that a five-minute session of proximal intercessory prayer (PIP) — in-person prayer offered by a trained volunteer — significantly reduced pain and anxiety in primary care patients compared to a music control group. The findings, published in the May/June 2026 issue of Annals of Family Medicine, suggest that proximal intercessory prayer may offer a practical, non-pharmacologic complement to conventional care, particularly for underserved populations.
Thursday, May 21, 2026
Study Sheds Light On How Early Pancreas Lesions Become Cancerous
In an unexpected finding, a new study flips on its head researchers’ understanding of how precancerous pancreas lesions evolve into pancreatic cancer. The paradigm-changing discovery has tremendous implications for identifying people at higher risk of cancer or even, potentially stopping malignant transformation.
Tuesday, May 12, 2026
UM School of Medicine Receives $2.9 Million in Federal Funding for Advanced Microscopy to Accelerate Neuroscience Discoveries
The School of Medicine’s University of Maryland - Medicine Institute for Neuroscience Discovery (UM-MIND) has received $2.9 million in federal funding to build a leading-edge advanced microscopy facility designed to accelerate neuroscience discoveries and innovations.
Wednesday, April 29, 2026
Silver Spring Woman Becomes First Adult Sickle Cell Disease Patient in Maryland to Receive FDA-Approved Gene Therapy
A 41-year-old Silver Spring woman who has endured debilitating pain crises and frequent hospitalizations throughout much of her life as the result of sickle cell disease has been treated at the University of Maryland Medical Center (UMMC) with her own genetically engineered stem cells in an effort to prevent life-threatening complications and achieve a long-term cure. UMMC is the academic flagship hospital of the University of Maryland Medical System (UMMS).
Thursday, April 23, 2026
UM School of Medicine Researchers Uncover New Pathway Allowing Red Blood Cells to Make Hemoglobin Under Stress
Scientists have long been puzzled by how maturing red blood cells manage to produce all the hemoglobin they need to carry oxygen to tissues, even after shedding the vital structures they need to produce it. Now, new University of Maryland School of Medicine (UMSOM) research has found a missing piece to the puzzle: In the final stages of their maturation, red blood cells can import heme, a crucial, iron-containing component of hemoglobin, from other cells. This surprising finding not only overturns long-standing assumptions about heme and red blood cells but could eventually lead to new therapies for inherited genetic blood disorders such as β-thalassemia.